AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

AbbVie Inc.NYSE: ABBV

Deferred Income Tax · Q2 FY2026 · quarter ended Jun 2026

Deferred income tax declines year over year

Q2 FY2026 deferred income tax of $195M (cash outflow) fell 28.3% year over year, ahead of the -81.4% change in trailing-twelve-month deferred income tax. Over 3 fiscal years it compounded at -36.6% a year.

Context

  • Deferred income tax amounted to 0.8% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Deferred income tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -28.3% holds above the trailing-twelve-month pace of -81.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$195M-242.3% QoQ
Last fiscal yearDec 2025
-$492M-66.0% YoY
LTMJun 2026
-$250M-81.4% YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.3%——
1 year-66.0%——
3-year CAGR-36.6%——
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
(492M) USD
Year-over-year change
+66.0%

Deferred Income Tax vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -81.4% is the 7th highest of 8, against a peer median of -51.8%.
  • Deferred income tax amounts to 0.4% of revenue for ABBV, versus a peer median of 1.6%.
ABBV Competitors
Deferred Income Tax for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$5.79B USD-211.3%—5.8%
PFEPfizer Inc.LTM Jun 2026$2.53B USD+39.5%-17.2%4.0%
MRKMerck & Co., Inc.LTM Jun 2026$1.07B USD-35.1%+2.1%1.6%
NVSNovartis AGLTM Jun 2026$949M USD-51.8%—1.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$785M USD-37.7%-29.4%1.6%
LLYEli Lilly and CompanyLTM Jun 2026$679.7M USD-76.2%-7.9%0.9%
AMGNAmgen Inc.LTM Jun 2026$516M USD-53.8%-15.6%1.4%
ABBVAbbVie Inc.LTM Jun 2026$250M USD-81.4%-36.6%0.4%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding ABBV) —-51.8%-15.6%1.6%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.55B11.85B4.82B4.29B4.23B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
Deferred Income Tax(898M)(1.93B)(2.89B)(1.45B)(492M)
Stock-Based Compensation692M671M747M911M955M
Change in Working Capital(1.32B)(258M)2.81B(2.78B)(2.36B)
Accounts Receivables(1.32B)(1.46B)66M207M(1.49B)
Inventory(142M)(686M)(417M)(319M)(234M)
Accounts Payables1.63B1.61B3.84B177M951M
Other Working Capital(1.49B)278M(676M)(2.85B)(1.59B)
Other Non-Cash Items4.24B6.15B8.65B9.45B8.6B
Operating Cash Flow22.78B24.94B22.84B18.81B19.03B
Capital Expenditures(787M)(695M)(777M)(974M)(1.21B)
Acquisitions (Net)(1.9B)(794M)(1.22B)(17.49B)(204M)
Purchases of Investments(119M)(1.44B)(77M)(73M)(35M)
Sales of Investments98M1.53B55M555M76M
Other Investing Activities366M774M13M(2.84B)(5.27B)
Investing Cash Flow(2.34B)(623M)(2.01B)(20.82B)(6.64B)
Debt Repayment(8.41B)(12.43B)(4.15B)7.35B(327M)
Common Stock Issued0000172M
Common Stock Repurchased(934M)(1.49B)(1.97B)(1.71B)(980M)
Dividends Paid(9.26B)(10.04B)(10.54B)(11.03B)(11.66B)
Other Financing Activities(430M)(840M)(562M)172M68M
Financing Cash Flow(19.04B)(24.8B)(17.22B)(5.21B)(12.72B)
Effect of Forex Changes(97M)(62M)5M(65M)42M
Net Change in Cash1.3B(545M)3.61B(7.29B)(295M)
Free Cash Flow21.99B24.25B22.06B17.83B17.82B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.